

November 11, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Outcome of Board Meeting – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A Sub-Para 4 of Schedule III, Regulation 33 and Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and in continuation to the Intimation given by the Company on November 05, 2024 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. November 11, 2024 (commenced at 12:30 P.M. (IST) and concluded at 02:40 P.M. (IST) has *inter-alia* considered and approved the below mentioned matters:

1. Unaudited Limited Reviewed Financial Results along with the Statements of Assets & Liabilities and Cash Flow (Standalone & Consolidated) of the Company for the Quarter-II and Half Year ended on September 30, 2024 of Financial Year 2024-25 along with Limited Review Reports issued by M/s. Singhi & Co., Statutory Auditors of the Company, are enclosed herewith as **Annexure-I**.
2. Statement of deviation or variation for Quarter-II of Financial Year 2024-25, ended on September 30, 2024, is annexed herewith as **Annexure-II**.

These are also being made available on the website of the Company i.e. <https://www.orchidpharma.com/index.html>

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**


Kapi Dayya
Company Secretary & Compliance Officer

Encl. as above



Orchid Pharma Limited

Regd. Office: Plot Nos. 121 – 128, 128A – 133, 138 – 151, 159 – 164, SIDCO Industrial Estate, Alathur, Chengalpattu District – 603110, Tamil Nadu, India

Ph. +91 - 44 - 2744 4471 - 78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com

CIN : L24222TN1992PLC022994

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024

(All amounts are in lakhs of Indian Rupees, unless otherwise stated)

S. No.	Particulars	Standalone financial results						Consolidated financial results					
		For the quarter ended			Six month ended		For the year ended	For the quarter ended			Six month ended		For the year ended
		Sept 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	Sept 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	March 31, 2024 (Audited)	Sept 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	Sept 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	March 31, 2024 (Audited)
1	Income from Operations												
2	Net Sales / Income from operations	22,269.86	24,440.61	19,875.53	46,710.47	38,167.51	81,936.82	22,269.86	24,440.61	19,875.53	46,710.47	38,167.51	81,936.82
3	Other Income	796.32	777.19	818.25	1,573.51	1,006.82	3,038.94	751.68	757.07	835.55	1,508.75	1,024.12	3,086.28
4	Total Income (1+2)	23,066.18	25,217.80	20,693.78	48,283.98	39,174.33	84,975.76	23,021.54	25,197.68	20,711.08	48,219.22	39,191.63	85,023.10
5	Expenses												
6	Cost of materials consumed	15,372.22	15,277.25	11,785.74	30,649.47	23,626.99	52,835.31	15,372.22	15,277.25	11,785.74	30,649.47	23,626.99	52,835.31
7	Changes in inventories of raw material, work-in-progress, stock-in-trade and finished goods	(2,256.18)	(251.81)	447.27	(2,507.99)	(187.21)	(4,389.40)	(2,256.18)	(251.81)	447.27	(2,507.99)	(187.21)	(4,389.40)
8	Employee benefit expenses	2,068.61	2,137.37	1,719.22	4,205.98	3,341.28	6,964.17	2,005.88	2,200.10	1,755.93	4,205.98	3,377.39	6,964.17
9	Finance costs	329.63	347.34	379.80	676.97	934.34	1,632.75	332.92	349.84	380.46	682.76	935.30	1,635.45
10	Depreciation and amortization expense	862.52	844.39	784.09	1,706.91	1,554.84	3,321.90	862.52	844.39	784.09	1,706.91	1,554.34	3,323.71
11	Other expenses	4,126.80	3,953.00	3,553.49	8,079.80	6,802.41	15,458.70	4,114.14	3,965.88	3,555.21	8,080.02	6,804.13	15,459.34
12	Total Expenses	20,503.60	22,307.54	18,669.61	42,811.14	36,072.65	75,823.43	20,431.50	22,385.65	18,708.70	42,817.15	36,111.74	75,828.58
13	Profit / (Loss) before exceptional items and tax (3-4)	2,562.58	2,910.26	2,024.17	5,472.84	3,101.68	9,152.33	2,590.04	2,812.03	2,002.38	5,402.07	3,079.89	9,194.52
14	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
15	Profit / (Loss) before tax (5+6)	2,562.58	2,910.26	2,024.17	5,472.84	3,101.68	9,152.33	2,590.04	2,812.03	2,002.38	5,402.07	3,079.89	9,194.52
16	Tax expense												
17	Current tax	-	-	-	-	-	-	-	-	-	-	-	10.71
18	Tax adjustments of earlier years	-	-	-	-	-	-	-	(15.41)	-	(15.41)	-	-
19	Deferred tax	-	-	-	-	-	(322.62)	-	-	-	-	-	(322.62)
20	Total Tax Expenses	-	-	-	-	-	(322.62)	-	(15.41)	-	(15.41)	-	(311.91)
21	Profit / (Loss) for the period before share of profit of Associates (7-8)	2,562.58	2,910.26	2,024.17	5,472.84	3,101.68	9,474.95	2,590.04	2,827.44	2,002.38	5,417.48	3,079.89	9,506.43



M. Shanmugam

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (Contd...)

S. No.	Particulars	Stand alone financial results						Consolidated financial results					
		For the quarter ended			Six month ended		For the year ended	For the quarter ended			Six month ended		For the year ended
		Sept 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	Sept 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	March 31, 2024 (Audited)	Sept 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	Sept 30, 2024 (Unaudited)	Sept 30, 2023 (Unaudited)	March 31, 2024 (Audited)
10	Profit / (Loss) for the period before share of profit of Associates	2,562.58	2,910.26	2,024.17	5,472.84	3,101.68	9,474.95	2,590.04	2,827.44	2,002.38	5,417.48	3,079.89	9,506.43
11	Add: Share of Profit/ (Loss) of Associates	-	-	-	-	-	-	133.61	107.62	(22.01)	241.23	(159.04)	(289.78)
12	Profit / (Loss) for the period (10+11)	2,562.58	2,910.26	2,024.17	5,472.84	3,101.68	9,474.95	2,723.65	2,935.06	1,980.37	5,658.71	2,920.85	9,216.65
13	Other comprehensive income, net of income tax												
	a) (i) items that will not be reclassified to profit or loss	(149.30)	(12.44)	(123.57)	(161.74)	(129.39)	(33.72)	(149.30)	(12.44)	(123.57)	(161.74)	(129.39)	(33.72)
	(ii) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	b) (i) items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	Total other comprehensive income/ (loss), net of income tax	(149.30)	(12.44)	(123.57)	(161.74)	(129.39)	(33.72)	(149.30)	(12.44)	(123.57)	(161.74)	(129.39)	(33.72)
14	Total comprehensive income/ (Loss) for the period (12+13)	2,413.28	2,897.82	1,900.60	5,311.10	2,972.29	9,441.23	2,574.35	2,922.62	1,856.80	5,496.97	2,791.46	9,182.93
15	Paid-up equity share capital	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91
	Other Equity						1,16,759.79						1,11,874.70
	Face value per share (Rs)	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
16	Earnings per equity share *: -												
	- Basic (Rs.)	5.05	5.74	4.40	10.79	6.74	19.59	5.37	5.79	4.30	11.16	6.35	19.06
	- Diluted (Rs.)	5.05	5.74	4.40	10.79	6.74	19.59	5.37	5.79	4.30	11.16	6.35	19.06

* * EPS for the quarters are not annualised




Hhanku

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (Contd...)


Statement of assets and liabilities				
Particulars	(in lakhs)			
	Standalone		Consolidated	
	As at September 30, 2024 (Un audited)	As at March 31, 2024 (Audited)	As at September 30, 2024 (Un audited)	As at March 31, 2024 (Audited)
ASSETS				
Non-current assets				
Property, plant and equipment	61,306.98	61,512.13	63,062.60	61,892.39
Intangible assets	61.00	64.08	61.00	64.08
Capital work in progress	1,794.16	1,018.27	2,502.04	1,639.39
Intangible Assets under Development	1,466.83	1,427.77	1,798.44	1,427.77
Right to use assets	50.18	66.91	50.18	66.91
Financial assets				
Investments	6,935.01	6,939.79	4,818.84	4,582.39
Loans to Subsidiaries	2,935.78	-	-	-
Other financial assets	431.72	596.37	431.72	596.37
Non current tax assets (net)	5,130.15	5,130.15	5,130.15	5,130.15
Other non-current assets	1,313.34	235.89	2,322.87	912.93
Total non-current assets	81,425.15	76,991.36	80,177.84	76,312.38
Current assets				
Inventories	32,057.88	26,422.61	32,057.88	26,422.61
Financial assets				
Trade receivables	20,899.31	18,937.04	21,519.93	19,554.71
Cash and cash equivalents	102.88	29.47	435.31	360.09
Bank balances other than above	23,350.19	25,693.26	23,953.35	26,296.42
Loans	-	788.97	-	-
Other financial assets	389.80	434.68	405.60	450.48
Current tax assets (net)	74.91	168.93	81.35	164.32
Other current assets	4,746.47	5,754.09	4,883.15	5,826.38
Total current assets	81,621.44	78,229.05	83,336.57	79,075.01
TOTAL ASSETS	1,63,046.59	1,55,220.41	1,63,514.41	1,55,387.39



Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (Contd...)

Statement of assets and liabilities (Contd..)					(in lakhs)
Particulars	Standalone		Consolidated		
	As at September 30, 2024 (Un audited)	As at March 31, 2024 (Audited)	As at September 30, 2024 (Un audited)	As at March 31, 2024 (Audited)	
EQUITY AND LIABILITIES					
Equity					
Equity share capital	5,071.91	5,071.91	5,071.91	5,071.91	
Other equity	1,22,070.89	1,16,759.79	1,17,352.41	1,11,874.70	
Total equity	1,27,142.80	1,21,831.70	1,22,424.32	1,16,946.61	
Liabilities					
Non-current liabilities					
Financial liabilities					
Borrowings	12,593.81	12,020.91	12,593.81	12,042.98	
Lease liabilities	20.34	37.00	20.34	37.00	
Provisions	365.81	363.37	365.81	363.37	
Total non-current liabilities	12,979.96	12,421.28	12,979.96	12,443.35	
Current liabilities					
Financial liabilities					
Borrowings	3,699.27	1,404.75	3,846.31	1,404.75	
Lease liabilities	33.33	33.33	33.33	33.33	
Trade payables					
- Outstanding Dues of Micro and Small Enterprises	1,174.55	866.53	1,174.55	866.53	
- Outstanding Dues of Creditors other than Micro and Small Enterprises	16,182.03	17,072.35	21,207.92	22,091.16	
Short term provisions	137.34	208.47	137.34	208.47	
Other current liabilities	1,697.31	1,382.00	1,710.68	1,393.19	
Total current liabilities	22,923.83	20,967.43	28,110.13	25,997.43	
Total Liabilities	35,903.79	33,388.71	41,090.09	38,440.78	
TOTAL EQUITY AND LIABILITIES	1,63,046.59	1,55,220.41	1,63,514.41	1,55,387.39	



Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (Contd...)

Standalone and Consolidated Statement of cash flows				
Particulars	(in lakhs)			
	Standalone		Consolidated	
	For the Half Year ended Sept 30, 2024 (Unaudited)	For the Half Year ended Sept 30, 2023 (Unaudited)	For the Half Year ended Sept 30, 2024 (Unaudited)	For the Half Year ended Sept 30, 2023 (Unaudited)
Cash Flow From Operating Activities				
Profit/ loss before income tax	5,472.84	3,101.68	5,643.30	2,920.85
Adjustments for				
Depreciation and amortisation expense	1,706.91	1,554.84	1,706.91	1,554.84
Interest income	(1,041.90)	(520.32)	(977.14)	(537.62)
Unrealised forex gain/ (loss)	62.57	357.77	43.31	291.26
Allowance for expected credit loss	24.27	(23.55)	24.27	(23.55)
Finance costs	676.97	934.34	682.76	935.00
Share of loss from associates under equity method	-	-	(241.23)	159.04
	6,901.66	5,404.76	6,882.18	5,299.82
Change in operating assets and liabilities				
(Increase)/ decrease in Other financial assets	(1,937.28)	(26.92)	209.53	(370.54)
(Increase)/ decrease in inventories	(5,635.27)	637.73	(5,635.27)	637.73
(Increase)/ decrease in trade receivables	(2,033.96)	3,073.55	(2,036.91)	2,760.65
(Increase)/ decrease in Other assets	(69.83)	(803.95)	(466.71)	(1,838.00)
Increase/ (decrease) in provisions and other liabilities	118.06	(1,306.24)	120.24	(1,193.95)
Increase/ (decrease) in trade payables	(498.82)	4,192.44	(491.74)	4,328.64
Cash generated from operations	(3,155.44)	11,171.37	(1,418.68)	9,624.35
Add : Income taxes received (net of payments)	(94.00)	(8.17)	(94.00)	(8.17)
Net cash from operating activities (A)	(3,249.44)	11,163.20	(1,512.68)	9,616.18
Cash Flows From Investing Activities				
Purchase of Property, plant and equipment (including changes in CWIP)	(2,297.45)	(2,607.52)	(4,086.82)	(2,340.18)
(Purchase)/ disposal proceeds of Investments	-	(1,922.78)	-	(263.84)
(Investments in)/ Maturity of fixed deposits with banks	2,343.07	(25,345.37)	2,343.07	(25,545.37)
Interest received	1,086.78	520.45	1,022.02	537.62
Net cash used in investing activities (B)	1,132.40	(29,355.22)	(721.73)	(27,611.77)
Cash Flows From Financing Activities				
Proceeds from issue of equity share capital (net of share issue expenses)	-	39,194.21	-	39,194.21
Proceeds / (Repayment) of Short term Borrowings (net)	2,294.52	-	2,419.49	-
Proceeds / (Repayment) of Long term Borrowings (net)	-	(18,481.41)	-	(18,481.41)
Finance costs	(104.07)	(934.34)	(109.86)	(935.00)
Net cash from/ (used in) financing activities (C)	2,190.45	19,778.46	2,309.63	19,777.80
Net increase/decrease in cash and cash equivalents (A+B+C)	73.41	1,586.44	75.22	1,782.21
Cash and cash equivalents at the beginning of the financial year	29.47	1,830.77	360.09	2,259.71
Cash and cash equivalents at end of the period	102.88	3,417.21	435.31	4,041.92



Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (Contd...)

Notes:

- 1 The above results for the quarter and half year ended Sept 30, 2024 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on November 11, 2024. The statutory auditors of the company have expressed a modified conclusion on the Limited review.
- 2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable.
- 3 99,02,705 fully paid up Equity Shares of face value ₹ 10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised.

As on September 30, 2024 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below :

Statement of QIP Net Funds raised and utilisation				
Particulars	Amount as stated in the Offer Document (Rs. in Lakhs)	Total amount utilised upto September 30, 2024 (Rs. In Lakhs)	* Balance amount as on September 30, 2024 kept in Fixed deposits (Rs. In Lakhs)	Remarks
1) Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility	9000	1,120	7880	
2) Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	14100	14100	-	
3) Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	9982	36	9946	
4) General corporate purposes	6098	3,768	2604	#
Total	39180	19024	20430	

#As per the QIP offer document the amount allocated for General Corporate Purpose (GCP) was ₹ 6098 Lakhs which was based on the proposed net proceeds after issue expenses being ₹ 39180 Lakhs. However, net proceeds transferred to Monitoring Account was ₹ 39454 Lakhs as against the proposed Net Proceeds of ₹ 39180 Lakhs, therefore the surplus amount of ₹ 274 Lakhs has been included in the GCP Balance as on 30th September, 2024

* Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits.

- 4 The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable.
- 5 The Company has submitted a petition with the Hon'ble National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited ("the Amalgamating Company") with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013. The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited ("stock exchanges") giving No objection to the said amalgamation.
- 6 Figures of the previous period have been regrouped/reclassified /restated wherever considered necessary

Place: Chennai
Date : Novemeber 11, 2024



For and on behalf of the Board

Manish Dhanuka

Manish Dhanuka
Managing Director



Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the Company for the quarter ended September 30, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone and Consolidated Financial Results of **Orchid Pharma Limited** ("the Company") for the quarter and half year ended September 30, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Emphasis of Matter:

We draw attention to:

Certain lands taken on lease by the Company for its operations in respect of which the lease agreement expired before the date of commencement of the Corporate Insolvency Resolution Process. As part of the right to review the existing agreements, the Company has made a detailed assessment of the market rent for the property and the market value of the property for outright purchase. Since the present rent as per erstwhile lease agreements is significantly high considering the market value of the property itself, the Company is in talks with the lessor for renewal of the lease with lower rent or for outright purchase of the property as part of the implementation of the resolution plan. However, no finality is reached on this matter as of date;

Our conclusion is not modified in respect of the above matter.



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards ('IND AS') prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

Place: Mumbai

Date: November 11, 2024



For Singhi & Co.
Chartered Accountants
Firm Regn. No. 302049E

A handwritten signature in blue ink, appearing to read 'Sudesh Choraria', written over a light-colored rectangular background.

Sudesh Choraria
Partner

Membership No. 204936
UDIN: 24204936BKGEJL6545

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone and Consolidated Financial Results of **Orchid Pharma Limited** (hereinafter referred to as "the Parent Company") and its subsidiaries (the Parent Company and its Subsidiaries together referred to as " the Group") and its associate for the quarter and half year ended September 30, 2024 ("the Statement") attached herewith being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent Company's Management and has been approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to issue a conclusion on these financial results based on the review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i) Orchid Pharmaceuticals Inc., USA
 - ii) Bexel Pharmaceuticals Inc., USA
 - iii) Orchid Pharmaceuticals SA(Proprietary) Limited, South Africa (Upto 31st January 2024)
 - iv) Diakron Pharmaceuticals, Inc. USA
 - v) Orchid Bio-Pharma Limited



5. Basis for Qualified Conclusion:

We draw attention to the following:

- a) The unaudited Consolidated financial results for the quarter and half year ended September 30, 2024 include the financial results for the quarter and half year ended September 30, 2024 of the following subsidiary companies, accounted on a line by line consolidation method:
 - i) Orchid Pharmaceuticals Inc., USA
 - ii) Bexel Pharmaceuticals Inc., USA
 - iii) Orchid Pharmaceuticals SA(Proprietary) Limited, South Africa (Upto 31st January 2024)
 - iv) Diakron Pharmaceuticals, Inc. USA
 - v) Orchid Bio-Pharma Limited

The unaudited consolidated financial results also include the results of M/s Orbion Pharmaceuticals Private Limited, an associate company accounted under equity method.

We did not review the interim financial results of the above subsidiaries whose financial information reflects total assets (before consolidation adjustments) of Rs.5519. 77 lakhs as at September 30 2024, revenue from operations of Rs. Nil and Rs.Nil, net profit after tax of Rs.27.46 Lacs and Rs. (-) 55.36 Lakhs, total comprehensive income after tax of Rs. 27.46 Lakhs and Rs. (-) 55.36 Lakhs for the quarter and half year ended September 30, 2024 respectively and net cash inflow of Rs.1.81 Lakhs for the half year ended September 30, 2024 as considered in the unaudited consolidated financial results. We also did not review the Group's share of net profit/ loss (after tax) of Rs. 133.61 Lakhs and Rs.241.23 Lakhs of the associate for the quarter and half year ended September 30, 2024 respectively, as considered in the unaudited consolidated financial results.

The financial information of the subsidiaries and associate are unaudited and have been furnished to us by the management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial results. Accordingly, we do not express any conclusion on the completeness and true and fair view of the financial results, including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries and associate and foreign currency translation reserve as at September 30, 2024 included in the unaudited consolidated financial results. This has also been qualified in the Limited Review reports of the earlier quarters and audit reports of the earlier years, audited by us.

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

6. Emphasis of Matter:

We draw attention to:

Certain lands taken on lease by the Parent Company for its operations in respect of which the lease agreement expired before the date of commencement of the Corporate Insolvency Resolution Process. As part of the right to review the existing agreements, the Parent Company has made a detailed assessment of the market rent for the property and the market value of the property for outright purchase. Since the present rent as per erstwhile lease agreements is significantly high considering the market value of the property itself, the Parent Company is in talks with the lessor for renewal of the lease with lower rent or for outright purchase of the property as part of the implementation of the resolution plan. However, no finality is reached on this matter as of date;

Our conclusion is not modified in respect of the above matter.



7. Based on our review conducted as above, except for the possible effects of the matters specified in Para 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai

Date: November 11, 2024



For Singhi & Co.,
Chartered Accountants
Firm Regn. No. 302049E

A handwritten signature in blue ink, appearing to read "Sudesh Choraria", written over a light yellow rectangular background.

Sudesh Choraria
Partner

Membership No.204936

UDIN: 24204936BKGEJM9867

STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Name of listed entity	Orchid Pharma Limited						
Mode of Fund Raising	Qualified Institutions Placement						
Date of Raising Funds	June 27, 2023						
Amount Raised	Rs.400 Crores						
Report filed for Quarter ended	September 30, 2024						
Monitoring Agency	Applicable						
Monitoring Agency Name, if applicable	Care Ratings Limited						
Is there a Deviation / Variation in use of funds raised	No						
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA						
If Yes, Date of shareholder Approval	NA						
Explanation for the Deviation / Variation	NA						
Comments of the Audit Committee after review	NA						
Comments of the auditors, if any	NA						
Objects for which funds have been raised and where there has been a deviation, in the following table	Investment in our wholly owned Subsidiary, Orchid Bio-Pharma Limited, ("OBPL") for setting up a new manufacturing facility in Jammu ("Jammu Manufacturing Facility"); Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by our Company; Funding capital expenditure requirements for setting up a new block at API Facility of the Company in Alathur, Tamil Nadu; and General corporate purposes.						
Sr. No.	Original Object	Modified Object, if any (Rs. in Lakhs)	Original Allocation (Rs. in Lakhs)	Modified allocation, if any (Rs. in Lakhs)	Funds Utilised (Rs. in Lakhs)	Amount of Deviation /Variation for the quarter according to applicable object (Rs. in Lakhs)	Remarks if any
1	Investment in OBPL for setting up Jammu Manufacturing Facility	No	9000	0	1120	0	
2	Repayment/prepayment, in full or in part, of certain outstanding	No	14100	0	14100	0	

	borrowings availed by our Company						
3	Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	No	9982	0	36	0	
4	General corporate purposes ("GCP")	No	6098*	0	3768	0	
* As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs. <i>Deviation or variation could mean:</i> (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.   Kapil Dayya Company Secretary & Compliance Officer							